Mylan-Biocon seek USFDA nod for biosimilar version of cancer drug
The proposed biosimilar version of trastuzumab is indicated for treatment of certain breast and gastric cancers
Latest News »
- Tesla said to reach pact with Shanghai for China production
- JK House sale: Raymond board to decide on future course of action, says Gautam Singhania
- Earthquake warning in US sent 92 years late
- Jet Airways expands codeshare pacts with Air France, KLM Royal Dutch and Delta
- Venkaiah Naidu wants cities to raise funds from local markets
Hyderabad: Drug makers Mylan NV and Biocon Ltd on Tuesday said they had submitted their first biologics licence application (BLA) to the US Food and Drug Administration (USFDA) seeking approval for a biosimilar version of cancer drug trastuzumab in the US.
The proposed biosimilar version of trastuzumab is indicated for treatment of certain breast and gastric cancers.
Mylan and Biocon said in a statement they believed that their application has the potential to be the first submission of a proposed biosimilar trastuzumab in the US
A biosimilar is a complex biological product that follows a different approval pathway compared to chemical drugs.
Biosimilars involve clinically testing the drug on animals and humans to demonstrate that the drug is highly similar to the innovator biological product (known as a reference product) and has no clinically meaningful differences in terms of safety and effectiveness from it.